(Reuters) -Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly’s weight-loss drug Zepbound to patients with obesity.
The company, in partnership with Lilly, will offer the vials to eligible patients at a self-pay price, Ro said.
In August, Lilly started selling vials of the lowest starter dose of Zepbound in the United States for $399 for a month’s supply through its direct-to-consumer website.
(Reporting by Sneha S K; Editing by Shounak Dasgupta)
Comments